FDA expands Olumiant approval for adolescents with severe alopecia areata
AI Summary- FDA expanded Olumiant approval to adolescents aged 12 and older with severe alopecia areata.
- 42% of patients taking 4 mg daily achieved at least 80% scalp hair coverage at 36 weeks.
- BRAVE-AA-PEDS data supported the decision, following U.S. adult approval in 2022.